Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Accounts Payables (2020 - 2026)

Design Therapeutics' Accounts Payables history spans 2 years, with the latest figure at $1.6 million for Q4 2021.

  • On a quarterly basis, Accounts Payables rose 15.8% to $1.6 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.6 million, a 15.8% increase, with the full-year FY2021 number at $1.6 million, up 15.8% from a year prior.
  • Accounts Payables hit $1.6 million in Q4 2021 for Design Therapeutics, down from $2.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for DSGN hit a ceiling of $2.2 million in Q3 2021 and a floor of $1.4 million in Q4 2020.